Medtronic results slightly ahead of estimates, guidance reiterated

Revenues rise 2.4% Y/Y in FQ2 for Medtronic (MDT) — the figure rises to 3.3% stripping out currency impact.

International sales tick 3% higher and accounted for 45% of MDT's top-line for the period.

"Revenue growth was in-line with our outlook for the year," CEO Omar Ishrak says, adding that the company is "performing at or better than the market in almost every one of [its] businesses."

Revenue growth by segment (constant currency): Cardiac and Vascular, +4%;  Restorative Therapies, +2%; Diabetes, +3%.

FY14 outlook: EPS guidance unchanged at $3.80-3.85 on revenue growth of 3-4%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs